Terms: = Ovarian cancer AND BMPR1A, ACVRLK3, 657, ENSG00000107779, P36894, ALK3, CD292 AND Treatment
21 results:
1. Who are the long-term survivors of recurrent ovarian carcinoma?: a retrospective analysis of a multicenter study.
Yoshihara M; Mogi K; Kitami K; Uno K; Iyoshi S; Tano S; Fujimoto H; Miyamoto E; Yoshikawa N; Emoto R; Matsui S; Kajiyama H
Int J Clin Oncol; 2022 Oct; 27(10):1660-1668. PubMed ID: 35906336
[TBL] [Abstract] [Full Text] [Related]
2. Regorafenib or Tamoxifen for platinum-sensitive recurrent ovarian cancer with rising CA125 and no evidence of clinical or RECIST progression: A GINECO randomized phase II trial (REGOVAR).
Trédan O; Provansal M; Abdeddaim C; Lardy-Cleaud A; Hardy-Bessard AC; Kalbacher E; Floquet A; Venat-Bouvet L; Lortholary A; Pop O; Frenel JS; Cancel M; Largillier R; Louvet C; You B; Zannetti A; Anota A; Treilleux I; Pissaloux D; Houlier A; Savoye AM; Mouret-Reynier MA; Meunier J; Levaché CB; Brocard F; Ray-Coquard I
Gynecol Oncol; 2022 Jan; 164(1):18-26. PubMed ID: 34696892
[TBL] [Abstract] [Full Text] [Related]
3. Time Trends in Receipt of Germline Genetic Testing and Results for Women Diagnosed With Breast cancer or ovarian cancer, 2012-2019.
Kurian AW; Ward KC; Abrahamse P; Bondarenko I; Hamilton AS; Deapen D; Morrow M; Berek JS; Hofer TP; Katz SJ
J Clin Oncol; 2021 May; 39(15):1631-1640. PubMed ID: 33560870
[TBL] [Abstract] [Full Text] [Related]
4. What Can Social Media Tell Us About Patient Symptoms: A Text-Mining Approach to Online ovarian cancer Forum.
Lee YJ; Park A; Roberge M; Donovan H
Cancer Nurs; 2022 Jan-Feb 01; 45(1):E27-E35. PubMed ID: 32649337
[TBL] [Abstract] [Full Text] [Related]
5. treatment and outcomes of a Danish ovarian cancer population.
Berg T; Nøttrup TJ; Peen UBS; Roed H
Dan Med J; 2020 Jan; 67(1):. PubMed ID: 31908253
[TBL] [Abstract] [Full Text] [Related]
6. A mathematical-descriptor of tumor-mesoscopic-structure from computed-tomography images annotates prognostic- and molecular-phenotypes of epithelial ovarian cancer.
Lu H; Arshad M; Thornton A; Avesani G; Cunnea P; Curry E; Kanavati F; Liang J; Nixon K; Williams ST; Hassan MA; Bowtell DDL; Gabra H; Fotopoulou C; Rockall A; Aboagye EO
Nat Commun; 2019 Feb; 10(1):764. PubMed ID: 30770825
[TBL] [Abstract] [Full Text] [Related]
7. Survival of Women With Type I and II Epithelial ovarian cancer Detected by Ultrasound Screening.
van Nagell JR; Burgess BT; Miller RW; Baldwin L; DeSimone CP; Ueland FR; Huang B; Chen Q; Kryscio RJ; Pavlik EJ
Obstet Gynecol; 2018 Nov; 132(5):1091-1100. PubMed ID: 30303916
[TBL] [Abstract] [Full Text] [Related]
8. Trends in Place of Death Among Patients With Gynecologic cancer in the United States.
Hicks-Courant K; Melamed A; Worley MJ; Kim YB; Schorge JO; Rauh-Hain JA
Obstet Gynecol; 2018 Jun; 131(6):1111-1120. PubMed ID: 29742673
[TBL] [Abstract] [Full Text] [Related]
9. Patterns of Müllerian Inhibiting Substance Type II and Candidate Type I Receptors in Epithelial ovarian cancer.
Basal E; Ayeni T; Zhang Q; Langstraat C; Donahoe PK; Pepin D; Yin X; Leof E; Cliby W
Curr Mol Med; 2016; 16(3):222-31. PubMed ID: 26917267
[TBL] [Abstract] [Full Text] [Related]
10. Small molecule inhibitor of the bone morphogenetic protein pathway DMH1 reduces ovarian cancer cell growth.
Hover LD; Young CD; Bhola NE; Wilson AJ; Khabele D; Hong CC; Moses HL; Owens P
Cancer Lett; 2015 Nov; 368(1):79-87. PubMed ID: 26235139
[TBL] [Abstract] [Full Text] [Related]
11. Genetic testing by cancer site: stomach.
Chun N; Ford JM
Cancer J; 2012; 18(4):355-63. PubMed ID: 22846738
[TBL] [Abstract] [Full Text] [Related]
12. BMP signalling controls the malignant potential of ascites-derived human epithelial ovarian cancer spheroids via AKT kinase activation.
Peart TM; Correa RJ; Valdes YR; Dimattia GE; Shepherd TG
Clin Exp Metastasis; 2012 Apr; 29(4):293-313. PubMed ID: 22249415
[TBL] [Abstract] [Full Text] [Related]
13. Anti-Müllerian hormone inhibits growth of AMH type II receptor-positive human ovarian granulosa cell tumor cells by activating apoptosis.
Anttonen M; Färkkilä A; Tauriala H; Kauppinen M; Maclaughlin DT; Unkila-Kallio L; Bützow R; Heikinheimo M
Lab Invest; 2011 Nov; 91(11):1605-14. PubMed ID: 21808236
[TBL] [Abstract] [Full Text] [Related]
14. Targeting slow-proliferating ovarian cancer cells.
Kondoh E; Mori S; Yamaguchi K; Baba T; Matsumura N; Cory Barnett J; Whitaker RS; Konishi I; Fujii S; Berchuck A; Murphy SK
Int J Cancer; 2010 May; 126(10):2448-56. PubMed ID: 19795452
[TBL] [Abstract] [Full Text] [Related]
15. One- and two-photon activated phototoxicity of conjugated porphyrin dimers with high two-photon absorption cross sections.
Dahlstedt E; Collins HA; Balaz M; Kuimova MK; Khurana M; Wilson BC; Phillips D; Anderson HL
Org Biomol Chem; 2009 Mar; 7(5):897-904. PubMed ID: 19225672
[TBL] [Abstract] [Full Text] [Related]
16. [First observations of the dose-dense weekly docetaxel therapy in relapsed ovarian cancer].
Lehoczky O; Pulay T
Magy Onkol; 2006; 50(1):43-6. PubMed ID: 16617383
[TBL] [Abstract] [Full Text] [Related]
17. [Hereditary colorectal cancer].
Park JG; Kim IJ
Korean J Gastroenterol; 2005 Feb; 45(2):78-87. PubMed ID: 15725711
[TBL] [Abstract] [Full Text] [Related]
18. Enhanced purification and production of Müllerian inhibiting substance for therapeutic applications.
Donahoe PK; Clarke T; Teixeira J; Maheswaran S; MacLaughlin DT
Mol Cell Endocrinol; 2003 Dec; 211(1-2):37-42. PubMed ID: 14656474
[TBL] [Abstract] [Full Text] [Related]
19. Long-term results from a phase II study of paclitaxel combined with doxorubicin in recurrent platinum refractory ovarian cancer.
Tropé C; Kristensen G; Kisic J; Kaern J
Eur J Gynaecol Oncol; 2001; 22(3):223-7. PubMed ID: 11501778
[TBL] [Abstract] [Full Text] [Related]
20. Management of ovarian cancer in patients older than 80 years of Age.
Cloven NG; Manetta A; Berman ML; Kohler MF; DiSaia PJ
Gynecol Oncol; 1999 Apr; 73(1):137-9. PubMed ID: 10094894
[TBL] [Abstract] [Full Text] [Related]
[Next]
